Latest Content

Chemoradiation Benefits for Cervical Cancer May Decline After Age 80

February 28th 2025, 8:00pm

By Spencer Feldman

Article

Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.

A Second Chance I Never Knew I Had After Lymphoma

February 28th 2025, 6:00pm

By Linda Cohen

Article

A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.

An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium

February 28th 2025, 5:00pm

By Dr. Chandler Park

Video

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

Pregnancy After Glioma Diagnosis Associated With Worse Progression Time

February 28th 2025, 4:00pm

By Alex Biese

Article

For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.

There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers

February 28th 2025, 2:00pm

By Ryan Scott

Article

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

Fractionated Reirradiation is Safe and Feasible in High-Grade Glioma

February 27th 2025, 10:00pm

By Ryan Scott

Article

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

February 27th 2025, 8:00pm

By Dr. Marwan Fakih

Article

The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.

My Cousin and I Journey Through Breast, Lung, Pancreatic and Prostate Cancer

February 27th 2025, 6:00pm

By Sue McCarthy

Article

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes

February 27th 2025, 4:00pm

By Spencer Feldman

Article

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer

February 27th 2025, 2:00pm

By Ryan Scott

Article

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.

Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma

February 26th 2025, 10:00pm

By Dr. Frederick L. Locke

Video

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.

A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies

February 26th 2025, 8:00pm

By Dr. Joseph Fraietta

Video

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

The Bittersweet Blessings of Being a Young Adult Cancer Survivor

February 26th 2025, 6:00pm

By Danielle Ripley-Burgess

Article

Being a young adult cancer survivor is bittersweet, bringing both unique struggles and unexpected blessings that shape my life, career and perspective.

Minimal Residual Disease Testing’s Variability Across Cancer Types

February 26th 2025, 5:00pm

By Dr. Christopher R. Flowers

Video

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.

What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar

February 26th 2025, 4:24pm

By Alex Biese

Video

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.